Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis. The study aims to assess adverse events and changes in disease activity by comparing oral upadacitinib to subcutaneous dupilumab in pediatric patients with moderate to severe atopic dermatitis, a condition characterized by skin inflammation, rash, and itching.
The interventions being tested are upadacitinib, an oral tablet or solution, and dupilumab, a subcutaneous injection. Upadacitinib is already approved for treating atopic dermatitis in patients aged 12 or older. The study will evaluate these treatments in younger children who require systemic therapy.
The study design is interventional and randomized with a parallel intervention model. It is single-masked, with the outcomes assessor being blinded, and the primary purpose is treatment. Approximately 675 participants will be enrolled across 150 sites worldwide.
The study began on August 19, 2024, with a primary completion date yet to be announced. The last update was on July 29, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This study could significantly impact AbbVie’s stock performance and investor sentiment, particularly if the results favor upadacitinib over dupilumab. The outcome could influence market dynamics, especially in the pediatric atopic dermatitis treatment space, where competition is keen.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.